A dermatology update on atopic dermatitis therapeutics, highlighting dupilumab, lebrikizumab, nemolizumab, rocatinlimab (OX40), amlitelimab (OX40L), rezpegaldesleukin, and oral JAK inhibitors (upadacitinib, abrocitinib).
A dermatology update on atopic dermatitis therapeutics, highlighting dupilumab, lebrikizumab, nemolizumab, rocatinlimab (OX40), amlitelimab (OX40L), rezpegaldesleukin, and oral JAK inhibitors (upadacitinib, abrocitinib).
A dermatology update on atopic...